The aim of this review is to justify the mechanistic backbone of WNT/β-catenin-mediated ICI resistance, as well as rationalizing a possibility of the application of WNT/β-catenin blockade as a combinatory regimen with anti-PD-(L)1 aiming at a durable anti-cancer therapy. This evidence concerns the gene CD274 and cancer.